Ipamorelin: the doses the studies actually used

The short version

This page describes what researchers gave to animals and to trial volunteers. It is not a how-to and it is not a recommendation. No human dose for ipamorelin is established, because the compound is not approved and the one human trial that tested a dose for an outcome did not work ^[3].

In plain terms: the human studies used a vein (IV), the animal studies mostly used a shot under the skin (subcutaneous) or into the belly, and the drug clears the body fast — roughly a two-hour half-life, meaning the blood level falls by half about every two hours ^[2]. The popular community routine of pairing it with CJC-1295 and injecting under the skin has no published human dosing basis at all. Where there is no number, this page says so rather than inventing one.

Doses used in the studies

Stated as studied, third person, by species and route:

• Human PK/PD study: 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg, IV over 15 minutes, single doses ^[2].
• Human Phase 2 ileus trial: 0.03 mg/kg IV twice daily for up to 7 days ^[3].
• Rat bone-growth study: 18, 90, and 450 micrograms per day, subcutaneous, divided three times daily, 15 days ^[4].
• Rat bone-mineral study: 0.5 mg/kg/day, continuous subcutaneous by osmotic minipump, 12 weeks.
• Rat postoperative-ileus model: 0.1–1 mg/kg IV, repeated four times daily.
• Ferret cachexia study (2024): 1–3 mg/kg, intraperitoneal ^[5].

These are experimental exposures in defined models. None is a human-use instruction.

Half-life and the GH pulse

In healthy human volunteers, ipamorelin showed a terminal half-life of about 2 hours (IV), with clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg ^[2]. The GH response is a single discrete pulse peaking at roughly 40 minutes (0.67 h) after dosing, then declining ^[2]. In rats, plasma clearance is roughly five-fold lower than GHRP-6. The short half-life is also why anti-doping reviewers flag it as an analytical challenge to detect ^[11]: it does not linger.

Routes studied

The research used several routes, with markedly different efficiency:

• Intravenous — human PK and the clinical trial; rodent efficacy ^[2][3].
• Subcutaneous — rodent bone and body-composition studies, and the dominant route in community use ^[4].
• Intranasal — characterized in rodents at roughly 20% bioavailability.
• Intraperitoneal — rodent and ferret efficacy studies ^[5].
• Oral — only for engineered ipamorelin-derived analogs (around 10% in dog); ipamorelin itself is not orally bioavailable. See route notes.

How much cjc-1295 ipamorelin should i take

There is no answerable dose. The question "how much cjc-1295 ipamorelin should i take" has no evidence-based answer: no controlled human trial has ever tested the CJC-1295 + ipamorelin combination for any outcome, so no studied human dose exists for the stack ^[3]. The community subcutaneous protocols that circulate online are anecdotal, have no peer-reviewed human dosing basis, and are not described here as recommendations. This site reports what studies measured; it does not issue protocols, and it does not tell anyone what to take.

How to reconstitute cjc-1295 ipamorelin 5mg

As a general research-handling observation — not a preparation instruction — ipamorelin is supplied as a lyophilized (freeze-dried) powder, free base or acetate salt, and is reconstituted with bacteriostatic water for laboratory handling. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These notes come from the research-supply literature and describe how the material behaves; they are not a clinical compounding procedure and not guidance for human use. The pharmacokinetic basis above ^[2] is the only human-relevant quantitative anchor.